Trial · NCT06235086
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
NCT06235086, Phase 3, Completed, CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus. Trials, record NCT06235086. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06235086
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
- NCT number
- NCT06235086
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 632 participants, actual
- Lead sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- TG103, Dulaglutide
- First posted
- 2024-01-31
- Last updated
- 2026-04-03
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in glycosylated hemoglobin (HbA1c) from baseline at 28 weeks of treatment | Baseline through Week28 | |
| Secondary | Changes in HbA1c from baseline at 52 weeks of treatment | Baseline through Week52 | |
| Secondary | The percentage of HbA1c≤6.5% and the percentage of HbA1c≤7% at week 28 and 52 | Week28 and 52 | |
| Secondary | Change in fasting plasma glucose (FPG) from baseline at week 28 and 52 | Baseline through Week28 and 52 | |
| Secondary | Change in weight from baseline at week 28 and 52 | Baseline through Week28 and 52 | |
| Secondary | Change in 2h-postprandial plasma glucose (2h-PPG) from baseline at week 28 and 52 | Baseline through Week28 and 52 | |
| Secondary | Mean 7 point blood glucose curve from baseline at week 28 and 52. Change in mean postprandial blood glucose increment from baseline at week 28 and 52. | Baseline through Week28 and 52 | |
| Secondary | Change in blood lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) from baseline at week 28 and 52. | Baseline through Week28 and 52 | |
| Secondary | Proportion of subjects receiving remedial therapy at week 28 and 52 | Week28 and 52 | |
| Secondary | Incidence of adverse events | Week-2 through 52 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06235086
GET https://conductscience.org/api/trials/v1/NCT06235086/registered